82.39
0.92 (1.13%)
| Previous Close | 81.47 |
| Open | 81.23 |
| Volume | 1,562,569 |
| Avg. Volume (3M) | 1,354,090 |
| Market Cap | 9,991,303,168 |
| Price / Earnings (TTM) | 25.99 |
| Price / Earnings (Forward) | 15.58 |
| Price / Sales | 0.790 |
| Price / Book | 2.89 |
| 52 Weeks Range | |
| Earnings Date | 4 May 2026 |
| Profit Margin | 3.21% |
| Operating Margin (TTM) | 5.75% |
| Diluted EPS (TTM) | 3.21 |
| Quarterly Revenue Growth (YOY) | -0.10% |
| Quarterly Earnings Growth (YOY) | 18.30% |
| Total Debt/Equity (MRQ) | 68.32% |
| Current Ratio (MRQ) | 1.38 |
| Operating Cash Flow (TTM) | 688.00 M |
| Levered Free Cash Flow (TTM) | 548.63 M |
| Return on Assets (TTM) | 4.61% |
| Return on Equity (TTM) | 8.47% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Distribution (US) | Bullish | Mixed |
| Medical Distribution (Global) | Bullish | Mixed | |
| Stock | Henry Schein, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | -4.0 |
| Price Volatility | -3.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 4.0 |
| Average | 0.20 |
|
Henry Schein Inc is a solutions company for healthcare professionals powered by a network of people and technology. The company is a provider of healthcare products and services to office-based dental and medical practitioners, as well as alternate sites of care. The company's reportable segments are Global Distribution and Value-Added Services; Global Specialty Products; and Global Technology. It generates the majority of its revenue from the Global Distribution and Value-Added Services segment, which includes distribution to the dental and medical markets of national brand and corporate brand merchandise, as well as equipment and related technical services. |
|
| Sector | Healthcare |
| Industry | Medical Distribution |
| Investment Style | Small Core |
| % Held by Insiders | 0.84% |
| % Held by Institutions | 107.70% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Southpoint Capital Advisors Lp | 31 Dec 2025 | 2,500,000 |
| Palestra Capital Management Llc | 31 Dec 2025 | 2,382,837 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 100.00 (Evercore ISI Group, 21.37%) | Buy |
| 100.00 (Baird, 21.37%) | Buy | |
| Median | 87.50 (6.20%) | |
| Low | 61.00 (Morgan Stanley, -25.96%) | Sell |
| Average | 88.50 (7.42%) | |
| Total | 5 Buy, 4 Hold, 1 Sell | |
| Avg. Price @ Call | 81.17 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Barrington Research | 25 Feb 2026 | 97.00 (17.73%) | Buy | 81.91 |
| Evercore ISI Group | 25 Feb 2026 | 100.00 (21.37%) | Buy | 81.91 |
| JP Morgan | 25 Feb 2026 | 92.00 (11.66%) | Buy | 81.91 |
| Mizuho | 25 Feb 2026 | 88.00 (6.81%) | Hold | 81.91 |
| 20 Jan 2026 | 81.00 (-1.69%) | Hold | 77.73 | |
| Morgan Stanley | 25 Feb 2026 | 61.00 (-25.96%) | Sell | 81.91 |
| UBS | 25 Feb 2026 | 87.00 (5.60%) | Hold | 81.91 |
| Wells Fargo | 25 Feb 2026 | 87.00 (5.60%) | Hold | 81.91 |
| Leerink Partners | 24 Feb 2026 | 87.00 (5.60%) | Hold | 83.35 |
| Baird | 23 Feb 2026 | 100.00 (21.37%) | Buy | 80.57 |
| Barclays | 09 Dec 2025 | 86.00 (4.38%) | Buy | 74.44 |
| Show more | ||||
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| BERGMAN STANLEY M | - | 81.93 | -49,131 | -4,012,625 |
| Aggregate Net Quantity | -49,131 | |||
| Aggregate Net Value ($) | -4,012,625 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 81.93 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| BERGMAN STANLEY M | Officer | 27 Feb 2026 | Sell (-) | 10,785 | 82.39 | 888,576 |
| BERGMAN STANLEY M | Officer | 26 Feb 2026 | Sell (-) | 38,346 | 81.47 | 3,124,049 |
| Date | Type | Details |
|---|---|---|
| 06 Feb 2026 | Announcement | A Legacy of Brighter Smiles: Celebrating 24 Years of the Give Kids A Smile Program |
| 22 Jan 2026 | Announcement | Henry Schein to Webcast Fourth Quarter 2025 Conference Call on Tuesday, February 24, 2026, at 8:00 A.M. ET |
| 15 Jan 2026 | Announcement | Henry Schein Enters Exclusive Distribution Agreement for CytoChip’s CLIA-Waived Hematology Analyzer |
| 12 Jan 2026 | Announcement | Henry Schein Names Frederick M. Lowery as Chief Executive Officer |
| 29 Dec 2025 | Announcement | Henry Schein to Participate in the J.P. Morgan Conference in January |
| 23 Dec 2025 | Announcement | Henry Schein Provides Update on CEO Search Process |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |